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A B S T R A C T
Background: Diagnostic timeliness in cancer patients is important for clinical outcomes and patient satisfaction
but, to-date, continuous monitoring of diagnostic intervals in nationwide incident cohorts has been impossible in
England.
Methods: We developed a new methodology for measuring the secondary care diagnostic interval (SCDI - ﬁrst
relevant secondary care contact to diagnosis) using linked cancer registration and healthcare utilisation data.
Using this method, we subsequently examined diagnostic timeliness in colorectal and lung cancer patients
(2014–15) by socio-demographic characteristics, diagnostic route and stage at diagnosis.
Results: The approach assigned SCDIs to 94.4% of all incident colorectal cancer cases [median length (90th
centile) of 25 (104) days] and 95.3% of lung cancer cases [36 (144) days]. Advanced stage patients had shorter
intervals (median, colorectal: stage 1 vs 4 - 34 vs 19 days; lung stage 1&2 vs 3B&4 - 70 vs 27 days). Routinely
referred patients had the longest (colorectal: 61, lung: 69 days) and emergency presenters the shortest intervals
(colorectal: 3, lung: 14 days). Comorbidities and additional diagnostic tests were also associated with longer
intervals.
Conclusion: This new method can enable repeatable nationwide measurement of cancer diagnostic timeliness in
England and identiﬁes actionable variation to inform early diagnosis interventions and target future research.
1. Introduction
Diagnosing cancer at early stages is associated with improved
cancer survival [1,2] and better patient experience [3]. Regardless of
stage, timely diagnosis is important, as tumours can progress whilst
patients wait [4], survival declines with increasing tumour size even
within the same TNM stage group [5] and shorter time intervals are
usually associated with better outcomes for most cancers [6]. Further-
more, if too much time elapses during cancer diagnosis a patient’s level
of ﬁtness could deteriorate post-presentation, and the likelihood of
them being ﬁt to undergo radical treatment such as surgery reduces [7].
Faster diagnosis for later stage cancer patients may allow earlier
symptom management and referral to palliative care or other support.
For many cancer patients, there is no routine monitoring of the
length of the diagnostic pathway (and therefore speed of diagnosis) and
any variation that exists allowing analysis or comparisons of change.
Across the UK, devolved nations are assessing their diagnostic pathways
and in England a proposed new metric will measure a particular cancer
diagnostic interval in secondary care for speciﬁcally referred patients
[8], increasing the importance of understanding these diagnostic
pathways.
In England currently, the 62 day wait operational standard
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incorporates the diagnostic pathway, from an urgent GP referral for
suspected cancer (Two Week Wait – TWW) or an urgent referral from
the NHS Cancer Screening Programmes [9] to receiving ﬁrst treatment.
The operational standard of 85% of patients meeting the 62 day wait has
not been achieved since 2014 [10]. Additionally, the 62 day wait only
monitors referrals under TWW or screening routes, which in 2015 was
43% of all diagnosed cancers. 42% of colorectal and 28% of lung cancer
patients are included in this target [11]. There is currently no routine
measure of the pre-diagnostic intervals for all cancer patients, which
would provide a more complete picture of diﬀerent diagnostic pathway
lengths.
Previous studies focusing on deﬁned pathway time intervals [6,12]
is plentiful, but increased availability of national level data allows ex-
amination of the entire secondary care diagnostic interval (SCDI) up to
diagnosis. The Routes to Diagnosis (RtD) study has transformed our
understanding of how patients are diagnosed [13] and identiﬁed initial
presentation routes leading to a cancer diagnosis, these being Two
Week Wait, Emergency Presentations, GP referral (routine), Other
Outpatient, Inpatient elective, Screen detected, Death Certiﬁcate Only
(DCO) and Unknown. RtD data has not been utilised previously to
calculate time intervals of the diagnostic pathway, indeed the RtD al-
gorithm identiﬁes the date of an initial event for each patient (such as
referrals to and outpatient hospital appointments) and provides the
start of a patient’s secondary care pathway enabling calculation of a
SCDI for all patients. Using linked Diagnostic Imaging Dataset (DID)
data to cancer registrations provides another useful source [14] for
identifying the ﬁrst part of the diagnostic pathway in secondary care.
The aim of this work is therefore twofold: to devise a methodology
to assign a SCDI for all cancer patients by determining the start and end
of the diagnostic pathway in secondary care and secondly to examine
variation and likely factors contributing to longer intervals for all pa-
tients diagnosed with two common cancers (colorectal and lung). This
will identify patient groups most at risk of prolonged diagnostic inter-
vals; inform the targeting of interventions or improvement eﬀorts
aimed at early diagnosis; drive further research; and monitor im-
provements.
2. Materials and methods
2.1. Data and exclusions
67 741 colorectal cancers (ICD10 codes: C18 – C20) and 74 904 lung
cancers (C33 – C34) diagnosed in English residents in 2014 and 2015
were identiﬁed using the cancer registration data held by the National
Cancer Registration and Analysis Service (NCRAS), Public Health
England (PHE) and formed our two cohorts of interest. Patients were
excluded (Fig. 1) if they were diagnosed via their death certiﬁcate, if
they had multiple tumours of the same site since 2012 or if, from the
RtD study, their diagnostic route was unknown [13] due to lack of
events prior to diagnosis. Following clinical advice, lung cancer patients
with an unclear stage 3 (i.e. a stage 3 coded as something other than 3A
or 3B) were also excluded.
Ethnicity was self-reported and submitted to the cancer registry
from hospital patient administration systems records. Deprivation
quintile was assigned using the income domain from the 2015 Index of
Multiple Deprivation [15]. The Charlson score was used for co-
morbidities identiﬁed in the timeframe in the cancer registration and
hospital records, combining the score of other deﬁned conditions (e.g.
diabetes, pulmonary disease, cardiovascular disease), using methods
previously described [16] with a diﬀerent time window between 27 and
3 months prior to cancer diagnosis [17]. Stage was categorised into
individual TNM stage groups 1, 2, 3 and 4 for colorectal cancer, whilst
for lung cancer patients, stage was regrouped into 1&2, 3A and 3B&4 to
better represent shared characteristics and treatment for early- and late-
stage lung cancers.
2.2. Data linkage
Our study builds on the RtD study linkage [13] to include further
diagnostic events and timings in order to calculate the SCDI. The cancer
registrations were linked at patient level to the following routine health
datasets, which provided dates and other information about speciﬁc
events taking place during diagnostic pathways:
- Cancer Waiting Times (CWT) [18] – used to assign urgent referrals
for suspected cancer (TWW) - referral to CWT, ﬁrst seen in sec-
ondary care
- Routes to Diagnosis (RtD) [13] – diagnostic route – referral to a
hospital outpatient appointment or hospital attendance
- Hospital Episode Statistics (HES) [19] – diagnostic procedures - in-
cluding colonoscopy and bronchoscopy
- Diagnostic Imaging Dataset (DID) [20] – diagnostic imaging – in-
cluding chest X-Rays (CXR) and chest Computed Tomography (CT)
scans
2.3. Determining the SCDI
In order to measure the SCDI, it is appropriate to follow a similar
method to the RtD study [13] and work back from the cancer diagnosis
record in order to determine the most likely start point of the diagnostic
pathway.
2.4. End of SCDI: diagnosis date
The end point of the diagnostic pathway, and of the SCDI, is a
cancer diagnosis, achieved for all on the cancer registry. Diagnosis dates
in cancer registries are determined by the European Network of Cancer
Registries (ENCR) rules, where a hierarchy of deﬁnitions of diagnosis is
used, the highest being the date of pathological veriﬁcation [21]. This
may be justiﬁed as the basis for robust and internationally comparable
statistics but is unhelpful for purposes of measuring diagnostic inter-
vals. This is because, in practice, for some patients the treating clin-
icians would reach a ﬁrm diagnosis of cancer (e.g. as indicated by in-
itiation of anti-cancer therapy) before the date of diagnosis according to
ENCR rules. There is also a signiﬁcant minority of patients in whom
there is no pathological conﬁrmation of a clinical diagnosis, in lung
cancers diagnosed in 2015 this was over a quarter of patients [22]. We
therefore considered the date of occurrence of a Multi-Disciplinary
Team (MDT) meeting, or recorded treatment referral or treatment in-
itiation, as deﬁning the diagnosis date if they occurred within the 28-
Fig. 1. Flow diagram to show the exclusions applied to the cohorts.
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day period before the date of diagnosis deﬁned by ENCR rules (Fig. 2).
If one of these events occurred more than 28 days before the diagnosis
date, we retained the registry diagnosis date, as the derived date was
likely to relate to a diﬀerent tumour. This approach resulted in re-as-
signing of the diagnosis date held in the cancer registry in 11% and 10%
of colorectal and lung patients, respectively.
2.5. Start of SCDI: deﬁnition of ﬁrst event
A start of the SCDI is also required in order calculate the interval.
For patients referred to an urgent pathway for suspected cancer (TWW)
and those diagnosed via screening there is a clear starting point of this
interval, well captured and monitored by NHS England as part of CWT
dataset [17]. For cancer registrations diagnosed via other diagnostic
routes there is no recorded start of this interval, so we established a ﬁrst
event for every patient using the possible events in the diagnostic
pathway in the linked data within 6 months before diagnosis (Fig. 2).
For each site, potential ﬁrst events in the diagnostic pathway were
deﬁned in consultation with clinicians, including veriﬁcation of re-
levant imaging and procedure codes and likely secondary care inter-
actions or events expected prior to colorectal and lung cancer diagnosis
(Appendix – Table A.0). The date of the ﬁrst event (e.g. HES outpatient
appointment, DID chest X-Ray) occurring in the six months before di-
agnosis was retained for each patient (Fig. 2). This time period chosen
was determined with clinical advice. Other diagnostic tests, in addition
to the ﬁrst event, were also investigated using DID and HES in relation
to the diagnostic pathway for both sites, these were CT Colonography
for colorectal cancer patients, and Positron Emission Tomography
(PET), Single Photon Emission Computerised Tomography (SPECT),
Bronchoscopy and Endobronchial Ultrasound (EBUS) for lung cancer
patients.
2.6. Statistical analysis
Descriptive statistics present the SCDI (calculated by subtraction
between SCDI end/start) by socio-demographic variable (age group,
sex, deprivation quintile and ethnicity), disease (stage, comorbidities)
and other factors (diagnostic route, other diagnostic events). The SCDI
was categorised into a ‘long/short’ length for statistical analysis, where
‘long’ was an interval greater than the median for that cancer site.
Two univariate logistic regression models investigated the associa-
tions between individual covariates and a long SCDI, for colorectal and
lung patients, respectively. Covariates were added into multivariate
logistic regression models. In the lung cancer model the number of
chest imaging procedures was also added. The covariates in the ﬁnal
model were determined by univariate analysis, previous literature and
advice from clinical colleagues. Likelihood ratio tests were carried out
to determine the overall signiﬁcance of the associations of each variable
with the outcome variable. Analysis was carried out using STATA v15
[23].
3. Results
A SCDI was calculated for 63 958 colorectal and 71 361 lung cancer
patients. The most common ﬁrst events identiﬁed as the start of this
interval for colorectal cancers were referral onto an urgent suspected
cancer pathway CWT & RtD referral on the same date (28%), referral to
a hospital outpatient appointment (RtD referral: 19%), CWT referral
(16%), hospital attendance (RtD start date: 15%) and colonoscopy
(7%). For lung cancer ﬁrst events were a relevant image (CXR or chest
CT: 61%) or a relevant image along with a CWT or RtD event on the
same day (17%). There were 362 (0.5%) colorectal and 165 (0.2%) lung
cancer patients where no event was found in the 6 months prior to
diagnosis and these were therefore excluded from the analysis (Fig. 1).
The median (Inter-Quartile Range – IQR; 90th centile) interval was
25 days (10–52; 104) and 36 days (15–85; 144) for colorectal and lung
cancer respectively. Tables 1 and 2 present SCDIs for patient-tumour
characteristics alongside regression analysis results for colorectal and
lung cancer respectively. The interval varied signiﬁcantly for both sites
by stage and diagnostic route. For both cancer sites, patients diagnosed
at early stage had longer median intervals than those diagnosed at late
stage (34 vs 19 days for stage 1 vs 4 colorectal cancers; 70 vs 27 days for
stage 1&2 vs 3B&4 lung cancers). This pattern was observed overall and
within each diagnostic route (Figs. 3 & 4 ).
By diagnostic route, the longest intervals were seen for those who
were diagnosed via routine GP referrals (colorectal cancer median 61
days; lung 69 days), followed by outpatients (colorectal cancer 49 days;
lung 66 days). The shortest intervals were seen in patients who were
diagnosed after an emergency presentation (3 days for colorectal can-
cers; 14 for lung), though, in the emergency route, 10% of patients had
intervals longer than 37 and 126 days for colorectal and lung cancer
respectively.
Patients with comorbidities had longer intervals, as did those with
additional diagnostic tests, where median intervals exceeded 50 days
for both sites.
There was strong evidence of association between diagnostic route
and interval after adjusting for other factors. Compared with patients
diagnosed via TWW, those diagnosed via an emergency had lower odds
of a long interval (OR 0.18 (95%CI [0.17–0.19]) for colorectal cancer,
0.36 [0.34–0.37] for lung). Patients diagnosed through routine GP re-
ferrals had signiﬁcantly higher odds of a long interval (4.43
[4.21–4.65] for colorectal cancer, 2.56 [2.43–2.69] for lung), as well as
patients diagnosed via the outpatient route (2.19 [2.03–2.35] for col-
orectal cancer and 2.00 [1.88–2.12] for lung). For both sites there was a
decreased likelihood of having a longer interval with advancing stage,
where stage 4 cancers had the lowest odds of a long interval (colorectal
Fig. 2. Calculation of the SCDI.
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cancer 0.56 [0.53–0.59]) compared with stage 1 and 0.38 [0.37–0.40]
for stage 3B&4 for lung compared with stage 1&2.
For both sites, patients with a Charlson comorbidity score of three
or more had increased odds of having a long SCDI compared with pa-
tients with no comorbidities (colorectal 1.33 [1.22–1.45], lung 2.46
[2.30–2.62]). Additional diagnostic procedures for colorectal and lung
cancer patients resulted in increased odds of a longer interval and lung
cancer patients having more than two chest x-rays or CT scans before
diagnosis had an OR of 5.25 [4.97–5.54] compared with only one CXR
or CT. The risk of having a long interval increased as patients got older,
peaking in 80–84 year olds for colorectal cancer (1.08 [1.00–1.16]) and
lung (1.18 [1.10–1.27]), before decreasing in the oldest age groups.
Female colorectal cancer patients had a higher odds of having a
longer interval (1.07 [1.03–1.11]), where no such pattern was found in
lung cancer patients. There was also an increased risk of having a longer
interval for colorectal cancer patients in more deprived quintiles, with
ORs of 1.09 [1.03–1.15] and 1.07 [1.00–1.13] for the two most de-
prived quintiles compared with the least deprived, where no signiﬁcant
associations were found for lung cancer.
4. Discussion
A secondary care diagnostic interval (SCDI) has been established for
the ﬁrst time for nearly all patients belonging to the English incident
cohort of colorectal and lung cancer patients, using robust decision-
rules to calculate the interval from ﬁrst relevant presentation/diag-
nostic test to diagnosis. The method is scalable to other cancer sites and
repeatable over time enabling continuous monitoring of diagnostic
timeliness nationwide.
The ﬁndings indicate that a large proportion of colorectal and lung
cancer patients experienced SCDIs exceeding 30 days. Early stage,
routine GP and outpatient diagnostic routes, greater number of
Table 1
Secondary care diagnostic interval (SCDI) & regression results: Colorectal cancer.
n (%) SCDI (days) centiles Unadjusted Adjusted
25th 50th 75th 90th OR (95% CI) OR (95% CI)
Total cohort 63 958 (100) 10 25 52 104
Age group p < 0.0001
<25 327 (0.5) 0 1 3 43 0.14 (0.10-0.19) 0.35 (0.24-0.52)
25-44 2 035 (3.2) 2 18 55 104 0.76 (0.69-0.84) 0.92 (0.81-1.04)
45-49 1 524 (2.4) 8 24 55.5 104 0.96 (0.86-1.08) 0.95 (0.83-1.09)
50-54 2 869 (4.5) 10 24 52 104 0.95 (0.87-1.04) 0.95 (0.86-1.05)
55-59 4 261 (6.7) 11 25 55 105 0.99 (0.91-1.07) 0.95 (0.87-1.04)
60-64 6 562 (10.3) 14 25 48 98 Reference
65-69 8 575 (13.4) 13 25 51 103 0.99 (0.93-1.05) 0.96 (0.90-1.04)
70-74 9 428 (14.7) 14 26 54 106 1.08 (1.02-1.15) 1.03 (0.96-1.11)
75-79 9 808 (15.3) 12 27 58 112 1.11 (1.04-1.18) 1.05 (0.98-1.13)
80-84 9 279 (14.5) 10 27 55 104 1.09 (1.03-1.17) 1.08 (1.00-1.16)
≥85 9 290 (14.5) 4 20 47 96 0.75 (0.70-0.80) 0.92 (0.85-0.99)
Sex p= 0.0002
Male 35 318 (55.2) 11 25 52 103 Reference
Female 28 640 (44.8) 9 25 53 105 0.99 (0.96-1.02) 1.07 (1.03-1.11)
Ethnicity p < 0.0001
White 57 851 (90.4) 11 25 53 104 Reference
Black 861 (1.4) 10 27 56 106 1.17 (1.03-1.34) 1.38 (1.18-1.62)
Asian 1 151 (1.8) 10 26 61 116 1.07 (0.95-1.20) 0.99 (0.86-1.13)
Mixed & other 9 879 (1.5) 10 25 50 108 1.03 (0.91-1.17) 1.09 (0.94-1.27)
Not known 3 116 (4.9) 7 21 42 89 0.77 (0.71-0.83) 0.85 (0.78-0.93)
Deprivation quintile p=0.0444
1 - least deprived 14 251 (22.3) 11 25 53 104 Reference
2 14 517 (22.7) 12 25 53 104 1.02 (0.97-1.07) 1.06 (1.00-1.11)
3 13 496 (21.1) 11 25 53 105 1.00 (0.95-1.05) 1.05 (0.99-1.11)
4 11 999 (18.8) 9 24 51 101 0.97 (0.92-1.01) 1.09 (1.03-1.15)
5 - most deprived 9 596 (15.6) 8 24 52 105 0.93 (0.88-0.98) 1.07 (1.00-1.13)
Stage p < 0.0001
1 10 184 (15.9) 18 34 75 126 Reference
2 15 212 (23.8) 13 27 55 105 0.67 (0.64-0.70) 0.81 (0.77-0.86)
3 17 189 (26.9) 13 25 51 100 0.61 (0.58-0.64) 0.72 (0.68-0.76)
4 14 892 (23.3) 5 19 37 80 0.38 (0.36-0.40) 0.56 (0.53-0.59)
unknown/other 6 481 (10.1) 3 19 50 108 0.44 (0.41-0.47) 0.68 (0.62-0.73)
Diagnostic route p < 0.0001
Emergency Presentation 15 469 (24.2) 1 3 12 37 0.17 (0.16-0.18) 0.18 (0.17-0.19)
GP Referral (routine) 15 183 (23.7) 31 61 102 143 4.31 (4.11-4.53) 4.43 (4.21-4.65)
Two Week Wait 20 755 (32.4) 17 25 38 61 Reference
Inpatient Elective 2 113 (3.3) 0 6 27 57 0.37 (0.33-0.41) 0.37 (0.34-0.41)
Other Outpatient 4 092 (6.4) 18 49 96 145 2.23 (2.08-2.40) 2.19 (2.03-2.35)
Screen detected 6 346 (9.9) 18 27 45 92 1.14 (1.08-1.21) 1.14 (1.07-1.21)
Charlson comorbidity score p < 0.0001
0 50 548 (79.0) 10 24 48 95 Reference
1 6 395 (10.0) 11 28 72 128 1.30 (1.24-1.37) 1.31 (1.24-1.40)
2 3 660 (5.7) 11 29 74 133 1.33 (1.24-1.42) 1.37 (1.27-1.49)
3+ 3 355 (5.3) 8 27 70 128 1.16 (1.08-1.24) 1.33 (1.22-1.45)
Additional diagnostics* p < 0.0001
No 59 394 (92.9) 9 23 49 101 Reference
Yes 4 564 (7.1) 30 50 86 126 4.98 (4.62-5.38) 4.58 (4.21-4.98)
Bold text – statistically signiﬁcant associations.
* Colorectal cancer additional tests in 6 months before diagnosis - CT Colonography.
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comorbidities and additional diagnostic investigations were all asso-
ciated with longer SCDIs. Shorter SCDIs for patients presenting via
emergency or TWW pathways were evident at all stages of disease, and
with advancing stage. For colorectal cancer, females and the more de-
prived had increased odds of having longer SCDIs, not evident in lung
cancer.
Our work expands on the RtD study, incorporating time to event-
based data used to deﬁne diagnostic route in order to establish diag-
nostic length [13]. While our work does not map exactly onto other
intervals which have been reported in the literature, such as the sec-
ondary care interval [11] or time from referral to secondary care to
diagnosis [6], it does provide a measurement of a key part of the di-
agnostic process for many cancer patients, the SCDI, incorporating tests
ordered in primary care which occur in a secondary care setting.
Studies using primary care data (from either electronic health re-
cords dataset or as part of a national audit initiative) have reported
relatively longer intervals than those reported in our study [24,25].
This could reﬂect that by their nature these studies were able to use
intervals with time points starting in primary care (unlike our method
which measures intervals from when the patient is ﬁrst seen in sec-
ondary care, even if for a test requested in primary care). Other prior
research has examined patient interval (symptom onset to presentation
to primary care) and primary care interval variation [26,27], but that
evidence is by necessity limited to pre-referral aspects of the diagnostic
process and is often sourced through bespoke data collection or non-
national sources.
Other conceptually similar attempts have been made in the US using
SEER-Medicare (claims) data [28], and in Denmark [29], using data
Table 2
Secondary care diagnostic interval (SCDI) & regression results: Lung cancer.
n (%) SCDI (days) centiles Unadjusted Adjusted
25th 50th 75th 90th OR (95% CI) OR (95% CI)
Total cohort 71 361 15 36 85 144
Age group p < 0.0001
<25 35 (0.1) 8 24 75 123 0.79 (0.40-1.54) 0.67 (0.29-1.54)
25-44 720 (1.0) 12 29.5 72 134.5 0.81 (0.69-0.94) 0.86 (0.71-1.03)
45-49 1 104 (1.6) 13 30 66 126 0.77 (0.68-0.88) 0.90 (0.77-1.04)
50-54 2 354 (3.3) 14 31 73 133 0.81 (0.74-0.89) 0.91 (0.82-1.02)
55-59 4 279 (6.0) 16 34 76 136 0.92 (0.85-0.99) 0.98 (0.90-1.07)
60-64 7 335 (10.3) 17 35 79 139 Reference
65-69 11 449 (16.0) 17 36 84 141 1.02 (0.96-1.08) 1.01 (0.94-1.08)
70-74 12 445 (17.4) 18 40 88 147 1.16 (1.09-1.22) 1.15 (1.07-1.23)
75-79 12 355 (17.3) 16 41 92 150 1.18 (1.11-1.25) 1.17 (1.09-1.25)
80-84 10 055 (14.1) 14 38 93 149 1.11 (1.05-1.18) 1.18 (1.10-1.27)
≥85 9 230 (12.9) 7 28 81 141 0.82 (0.77-0.88) 1.10 (1.02-1.19)
Sex p= 0.9836
Male 38 149 (53.5) 15 36 85 144 Reference
Female 33 212 (46.5) 14 36 85 144 0.98 (0.95-1.01) 1.00 (0.97-1.04)
Ethnicity p= 0.0002
White 65 763 (92.2) 15 37 86 145 Reference
Black 648 (0.9) 13 33 86 147 0.86 (0.74-1.01) 0.94 (0.78-1.13)
Asian 984 (1.4) 16 42 99 153 1.15 (1.01-1.31) 1.04 (0.89-1.21)
Mixed & other 891 (1.3) 13 31 75 133 0.81 (0.71-0.92) 0.90 (0.77-1.06)
Not known 3 075 (4.3) 9 25 61 128 0.60 (0.56-0.65) 0.82 (0.75-0.89)
Deprivation quintile p=0.2647
1 - least deprived 10 172 (14.3) 16 36 85 143 Reference
2 12 796 (17.9) 16 36 84 146 0.99 (0.94-1.05) 1.02 (0.96-1.08)
3 14 039 (19.7) 15 36 85 143 0.98 (0.94-1.04) 1.04 (0.97-1.10)
4 15 823 (22.2) 15 36 85 144 1.00 (0.95-1.05) 1.06 (1.00-1.13)
5 - most deprived 18 531 (26.0) 14 36 86 146 0.97 (0.92-1.02) 1.02 (0.96-1.08)
Stage p < 0.0001
1&2 16 521 (23.2) 34 70 123 162 Reference
3A 8 021 (11.2) 22 42 88 143 0.48 (0.45-0.50) 0.53 (0.50-0.57)
3B&4 41 506 (58.2) 11 27 61 124 0.25 (0.24-0.26) 0.38 (0.37-0.40)
unknown/other 5 313 (7.5) 8 38 104 155 0.39 (0.37-0.42) 0.70 (0.65-0.75)
Diagnostic route p < 0.0001
Emergency Presentation 24 906 (34.9) 4 14 52 126 0.48 (0.46-0.50) 0.36 (0.34-0.37)
GP Referral (routine) 16 657 (23.3) 32 69 126 163 2.59 (2.48-2.71) 2.56 (2.43-2.69)
Two Week Wait 20 415 (28.6) 22 35 63 107 Reference
Inpatient Elective 1 240 (1.7) 9 18 43 107 0.43 (0.37-0.48) 0.37 (0.32-0.43)
Other Outpatient 8 143 (11.4) 30 66 122 161 2.38 (2.25-2.51) 2.00 (1.88-2.12)
Charlson comorbidity score p < 0.0001
0 49 079 (68.8) 14 31 67 121 Reference
1 10 110 (14.2) 20 53 116 161 1.91 (1.83-2.00) 1.75 (1.66-1.84)
2 5 982 (8.4) 22 63 126 162 2.25 (2.12-2.38) 2.09 (1.95-2.23)
3+ 6 190 (8.7) 22 75 139 169 2.51 (2.37-2.65) 2.46 (2.30-2.62)
CXR and CT count p < 0.0001
0 4 766 (6.7) 5 15 41 96 0.60 (0.56-0.65) 0.55 (0.50-0.60)
1 10 540 (14.8) 7 25 58 114 Reference
2 27 295 (38.3) 12 26 52 110 0.92 (0.88-0.96) 0.98 (0.93-1.03)
3+ 28 760 (40.3) 31 67 123 161 3.84 (3.66-4.02) 5.25 (4.97-5.54)
Additional diagnostics* P < 0.0001
No 60 848 (85.3) 13 32 79 141 Reference
Yes 10 513 (14.7) 34 61 108 155 2.99 (2.85-3.12) 2.12 (2.01-2.24)
* Lung cancer additional tests in 6 months before diagnosis- PET, SPECT, Bronchoscopy, EBUS.
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from a well-characterised sub-regional cohort but the approach used in
our study has the beneﬁt of being more easily scalable and repeatable,
as it is based on linkage of national cancer registration and routine
healthcare utilisation data. This makes it the most comprehensive study
of SCDIs to date. Use of rich health datasets linked to established cancer
registrations achieves a more complete picture of diagnostic events of
cancer patients in secondary care, irrespective of route to diagnosis and
importantly includes the routine referral route, via which signiﬁcant
proportions of cancer patients are diagnosed. An important limitation is
that our interval begins at diagnostics or secondary care interactions,
Fig. 3. Secondary care diagnostic interval (SCDI) by diagnostic route and stage, Colorectal cancer.
Fig. 4. Secondary care diagnostic interval (SCDI) by diagnostic route and stage, Lung cancer.
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due to the lack of primary care data coverage for England, and so the
entire cancer diagnosis pathway is not captured. Additionally data
linkage issues probably accounted for the lack of ﬁrst event, and
therefore exclusion from SCDI calculations, for a very small proportion
of our cohorts.
Longer SCDIs were evident for lung cancer, explained partly by
diagnostics (CXR particularly) which can be requested in primary care
rather than the secondary care-based colorectal cancer diagnostics.
Between cancer sites comparisons are diﬃcult, however, due to dif-
ferences in both diagnostic procedures and symptom development [26].
The TWW pathway is by its design intended to confer a sense of ur-
gency, but the results suggest that the imperative for a patient to be
seen by a specialist within two weeks does not ensure a swift pathway
and diagnosis thereafter, with a quarter of colorectal and lung cancer
patients diagnosed via TWW having intervals longer than 38 and 63
days respectively. This may reﬂect post-assessment waiting for specia-
list tests due to capacity constraints [30], suboptimal test selection,
incomplete or inadequate tests (which may need to be repeated), or
alternative tests. Older and less ﬁt patients may also experience longer
than average intervals when preparation is needed for invasive in-
vestigations such as colonoscopy.
It is well recognised in the literature that shorter diagnostic inter-
vals are not always associated with better outcomes [6] and shorter
intervals for emergency presentations or later stage disease are likely
for patients with more pronounced symptoms, who are less likely to
have positive outcomes due to the severity of their disease [31,32]; the
sicker-quicker eﬀect. Patients who have experienced extended intervals
but have early stage disease may reﬂect less aggressive disease or could
be in line with an incidental ﬁnding of cancer, where symptoms ex-
perienced may not have actually been caused by the cancer but were
suﬃcient to prompt investigation during which cancer was detected.
Nevertheless, for patients other than those presenting with advanced
stage disease, shortening of SCDIs can help improve outcomes, in-
cluding survival [6] and mortality [33]. It may also lower the risk of
disease progression and can help improve their experience of the health
service.
There are many beneﬁts in using routine data surveillance of these
phenomena, allowing scalability, ability to monitor progress over time
and across patient groups. The same methodology can be applied to
other cancer sites, providing appropriate diagnostic tests are known, to
guide improvements in diagnostic care and capacity allocation.
Repetition with more recent cancer data would enable changes since
the implementation of the National Institute for Health and Care
Excellence (NICE) suspected cancer recognition and referral guidelines
in 2015 [34] to be assessed, speciﬁcally any impact on SCDIs. Further
reﬁnement of the approach could include measurement between dif-
ferent points along the diagnostic pathway, to further explore pinch
points and opportunities for service optimisation.
5. Conclusion
We address a substantial knowledge gap for earlier cancer diagnosis
by developing an approach to measure SCDIs in national incident co-
horts of cancer patients. In patients with colorectal or lung cancer,
signiﬁcant interval variation exists by various patient and disease fac-
tors. Our baseline measures of these intervals can help with under-
standing of complex disease, service, tumour and patient factors asso-
ciated with longer intervals. Knowledge of SCDIs oﬀers a baseline
assessment and a useful indication of the degree of improvement
needed, and where focus is required, in order to ensure patient diag-
nostic pathways are as rapid as possible to optimise patient experience
and potentially improve outcomes.
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